Mepolizumab responders and non-responders
Among MEPO subjects who completed their trials, 74.1%, (43/58) subjects were responders based on NICE criteria. At baseline, MEPO responders were on a significantly lower mOCS dose (supplementary Table E4) [Median(IQR), responder: 10(6) vs non-responder: 17(25), P=0.030], had better ACQ6 [Mean(SD), responder: 2.33(1.27) vs non-responder: 4(0.94), P <0.001] , better AQLQ [Mean(SD), responder: 4.53(1.19) vs non-responder 3.57(1.19), P=0.021] , and significantly less AHE [Median(IQR), responder: 0(1) vs non-responder : 1(4), P=0.030]. A smaller proportion of responders had multiple AHE [responder: 9.8%,(4/41) vs non-responder: 42.9%,(6/14), P=0.012] and depression [responder: 19.1%,(8/42) vs non-responder: 46.7%,(7/15), P=0.037]. In multivariate analysis (Table 2), only better ACQ6 at baseline was independently associated with MEPO response.